News
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), LOS ANGELES, Aug. 15, 2024 (GLOBE NEWSWIRE) — Biopharmaceuticals, Inc., a clinical-stage, multi-asset biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday, August 5, 2024, at 4:30 p.m. ET to report second-quarter 2024 financial results and provide an update on its business and pipeline.
To access the call, dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and enter conference ID 13747505, or click here. link and request a callback. The audio webcast can be accessed live at this link and also on the “Investor Relations” page of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on the Spero website for 30 days after the call.
About Spero Therapy
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections. For more information – www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media inquiries:
media@sperotherapeutics.com